S&P 500   3,819.72 (-1.31%)
DOW   31,270.09 (-0.39%)
QQQ   309.88 (-2.68%)
AAPL   122.43 (-2.15%)
MSFT   227.78 (-2.60%)
FB   256.06 (-1.14%)
GOOGL   2,013.77 (-2.46%)
TSLA   654.02 (-4.72%)
AMZN   3,009.35 (-2.75%)
NVDA   514.51 (-4.05%)
BABA   236.24 (+0.78%)
CGC   33.24 (-5.70%)
GE   13.52 (+4.16%)
MU   89.41 (-1.84%)
NIO   41.23 (-4.76%)
AMD   81.05 (-3.66%)
T   28.80 (+2.06%)
F   12.23 (-2.55%)
ACB   10.46 (-5.17%)
DIS   193.00 (-0.48%)
BA   229.25 (+2.74%)
NFLX   521.32 (-4.84%)
PFE   34.34 (+2.48%)
S&P 500   3,819.72 (-1.31%)
DOW   31,270.09 (-0.39%)
QQQ   309.88 (-2.68%)
AAPL   122.43 (-2.15%)
MSFT   227.78 (-2.60%)
FB   256.06 (-1.14%)
GOOGL   2,013.77 (-2.46%)
TSLA   654.02 (-4.72%)
AMZN   3,009.35 (-2.75%)
NVDA   514.51 (-4.05%)
BABA   236.24 (+0.78%)
CGC   33.24 (-5.70%)
GE   13.52 (+4.16%)
MU   89.41 (-1.84%)
NIO   41.23 (-4.76%)
AMD   81.05 (-3.66%)
T   28.80 (+2.06%)
F   12.23 (-2.55%)
ACB   10.46 (-5.17%)
DIS   193.00 (-0.48%)
BA   229.25 (+2.74%)
NFLX   521.32 (-4.84%)
PFE   34.34 (+2.48%)
S&P 500   3,819.72 (-1.31%)
DOW   31,270.09 (-0.39%)
QQQ   309.88 (-2.68%)
AAPL   122.43 (-2.15%)
MSFT   227.78 (-2.60%)
FB   256.06 (-1.14%)
GOOGL   2,013.77 (-2.46%)
TSLA   654.02 (-4.72%)
AMZN   3,009.35 (-2.75%)
NVDA   514.51 (-4.05%)
BABA   236.24 (+0.78%)
CGC   33.24 (-5.70%)
GE   13.52 (+4.16%)
MU   89.41 (-1.84%)
NIO   41.23 (-4.76%)
AMD   81.05 (-3.66%)
T   28.80 (+2.06%)
F   12.23 (-2.55%)
ACB   10.46 (-5.17%)
DIS   193.00 (-0.48%)
BA   229.25 (+2.74%)
NFLX   521.32 (-4.84%)
PFE   34.34 (+2.48%)
S&P 500   3,819.72 (-1.31%)
DOW   31,270.09 (-0.39%)
QQQ   309.88 (-2.68%)
AAPL   122.43 (-2.15%)
MSFT   227.78 (-2.60%)
FB   256.06 (-1.14%)
GOOGL   2,013.77 (-2.46%)
TSLA   654.02 (-4.72%)
AMZN   3,009.35 (-2.75%)
NVDA   514.51 (-4.05%)
BABA   236.24 (+0.78%)
CGC   33.24 (-5.70%)
GE   13.52 (+4.16%)
MU   89.41 (-1.84%)
NIO   41.23 (-4.76%)
AMD   81.05 (-3.66%)
T   28.80 (+2.06%)
F   12.23 (-2.55%)
ACB   10.46 (-5.17%)
DIS   193.00 (-0.48%)
BA   229.25 (+2.74%)
NFLX   521.32 (-4.84%)
PFE   34.34 (+2.48%)
Log in
NASDAQ:TLSA

Tiziana Life Sciences Stock Forecast, Price & News

$3.03
-0.16 (-5.02 %)
(As of 03/3/2021 03:54 PM ET)
Add
Compare
Today's Range
$3.01
Now: $3.03▼
$3.17
50-Day Range
$2.68
MA: $3.66▼
$4.73
52-Week Range
$0.62
Now: $3.03▼
$12.17
Volume1,576 shs
Average Volume1.50 million shs
Market Capitalization$194.59 million
P/E RatioN/A
Dividend YieldN/A
Beta1.41
Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat diseases in oncology and immunology in the United Kingdom. The company's product pipeline includes Foralumab (TZLS-401), a human anti-CD3 monclonal antibody for the treatment of autoimmune and inflammatory diseases, such GvHD, ulcerative colitis, Crohn's disease, multiple sclerosis, type-1 diabetes, inflammatory bowel diseases, psoriasis, and rheumatoid arthritis; and Milciclib (TZLS-201), which is an orally bioavailable, small molecule inhibitor of cyclin-dependent kinases and Src family kinases for the treatment of hepatocellular carcinoma. It also develops Anti IL-6r (TZLS-501), a human anti-interleukin-6 receptor monoclonal antibody for the treatment of IL6-induced inflammation, primarily to treat hospitalized COVID-19 patients with severe respiratory symptoms; and StemPrintER, a multi-gene signature assay intended for use in patients diagnosed with estrogen-receptor positive ER+/HER2 negative breast cancers. The company was founded in 2013 and is headquartered in London, the United Kingdom. Tiziana Life Sciences Plc is a subsidiary of Planwise Group Limited.
Tiziana Life Sciences logo

Headlines

Tiziana Life Sciences Plc: Tiziana Life Sciences Interview to Air on Bloomberg Television US on The RedChip Money Report
February 26, 2021 |  finanznachrichten.de
Tiziana Life Sciences Interview to Air on Bloomberg Television US on The RedChip Money Report
February 26, 2021 |  finance.yahoo.com
ASLAN Pharmaceuticals Appoints Dr Neil Graham as Independent Director
February 18, 2021 |  finance.yahoo.com
Tiziana Life Sciences Plc: Tiziana Life Sciences to Present at the BIO CEO & Investor Digital Conference
February 16, 2021 |  finanznachrichten.de
Tiziana Life's Foralumab shows positive action in Brazil COVID-19 study
February 3, 2021 |  seekingalpha.com
TLSA: COVID-19 Brazilian Study Topline Data Released
February 2, 2021 |  finance.yahoo.com
Tiziana Life Sciences' Shares Rally As Foralumab Shows Encouraging Action In COVID-19 Study In Brazil
February 2, 2021 |  finance.yahoo.com
Tiziana Reports Positive Data from the Clinical Study of Nasal Administration with Foralumab, its proprietary fully human anti-CD3 monoclonal antibody, in COVID-19 Patients in Brazil
February 2, 2021 |  finance.yahoo.com
Tiziana Life Sciences soars ahead of its admission to main market of LSE
January 30, 2021 |  seekingalpha.com
Tiziana Life Sciences plc ("Tiziana" or the "Company") - Tiziana Files Registration Statement on Form F-3 with U.S. Securities and Exchange Commission
January 27, 2021 |  finance.yahoo.com
Tiziana Life Sciences plc ("Tiziana" or the "Company") - AIM Delisting and Admission to the Standard Listing Segment of Main Market
January 21, 2021 |  benzinga.com
Tiziana Life Sciences Plc: Tiziana Life Sciences to participate at J.P. Morgan Healthcare Conference 2021
January 11, 2021 |  finanznachrichten.de
Tiziana Life Sciences PLC ("Tiziana" or "the Company") - Notification of proposed admission to the Main Market and cancellation of trading on AIM
December 17, 2020 |  benzinga.com
Tiziana Life Sciences PLC ("Tiziana" or "the Company") - Notification of proposed admission to the Main Market and cancellation of trading on AIM
December 17, 2020 |  benzinga.com
Tiziana Life Sciences PLC (“Tiziana” or “the Company”) - Notification of proposed admission to the Main Market and cancellation of trading on AIM
December 17, 2020 |  finance.yahoo.com
Tiziana Life Sciences PLC (“Tiziana” or “the Company”) - Notification of proposed admission to the Main Market and cancellation of trading on AIM
December 17, 2020 |  finance.yahoo.com
Tiziana Life Sciences to Host Investor Update Call on 2 December 2020 at 4:15 p.m. ET
December 1, 2020 |  finance.yahoo.com
Tiziana Life teams up with Parexel Biotech in inflammatory bowel disease
November 11, 2020 |  seekingalpha.com
Tiziana launches foralumab study for COVID-19 in Brazil; clinical data expected by year end
November 2, 2020 |  seekingalpha.com
Tiziana Life Sciences Announces Timetable of Demerger of Accustem (for holders of Tiziana ADRs)
October 27, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:TLSA
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.tizianalifesciences.com
Phone44-20-7495-2379
Employees8
Year FoundedN/A

Debt

Debt-to-Equity RatioN/A
Current Ratio1.86
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value($0.09) per share
Price / Book-33.67

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Outstanding Shares64,220,000
Market Cap$194.59 million
Next Earnings Date6/16/2021 (Estimated)
OptionableNot Optionable

MarketRank™

Overall MarketRank™

1.16 out of 5 stars

Medical Sector

891st out of 1,968 stocks

Pharmaceutical Preparations Industry

430th out of 772 stocks

Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$3.03
-0.16 (-5.02 %)
(As of 03/3/2021 03:54 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TLSA News and Ratings via Email

Sign-up to receive the latest news and ratings for TLSA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Tiziana Life Sciences (NASDAQ:TLSA) Frequently Asked Questions

Is Tiziana Life Sciences a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Tiziana Life Sciences in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Tiziana Life Sciences stock.
View analyst ratings for Tiziana Life Sciences or view top-rated stocks.

What stocks does MarketBeat like better than Tiziana Life Sciences?

Wall Street analysts have given Tiziana Life Sciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Tiziana Life Sciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Tiziana Life Sciences?

Tiziana Life Sciences saw a decrease in short interest during the month of January. As of January 29th, there was short interest totaling 221,700 shares, a decrease of 38.2% from the January 14th total of 358,900 shares. Based on an average daily trading volume, of 1,070,000 shares, the short-interest ratio is currently 0.2 days.
View Tiziana Life Sciences' Short Interest.

When is Tiziana Life Sciences' next earnings date?

Tiziana Life Sciences is scheduled to release its next quarterly earnings announcement on Wednesday, June 16th 2021.
View our earnings forecast for Tiziana Life Sciences.

How has Tiziana Life Sciences' stock been impacted by Coronavirus (COVID-19)?

Tiziana Life Sciences' stock was trading at $3.95 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, TLSA stock has decreased by 22.5% and is now trading at $3.06.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for TLSA?

2 Wall Street analysts have issued twelve-month price objectives for Tiziana Life Sciences' shares. Their forecasts range from $8.00 to $11.00. On average, they anticipate Tiziana Life Sciences' share price to reach $9.50 in the next twelve months. This suggests a possible upside of 210.5% from the stock's current price.
View analysts' price targets for Tiziana Life Sciences or view top-rated stocks among Wall Street analysts.

Who are Tiziana Life Sciences' key executives?

Tiziana Life Sciences' management team includes the following people:
  • Mr. Gabriele Marco Antonio Cerrone M.B.A., MBA, Founder & Exec. Chairman (Age 49, Pay $284.56k)
  • Dr. Kunwar Shailubhai, CEO, Chief Scientific Officer & Exec. Director (Age 63, Pay $810k)
  • Dr. Andrea Brancale, Scientific Founder
  • Mr. Richard Clarkson Ph.D., Scientific Founder
  • Mr. Andrew Westwell Ph.D., Scientific Founder
  • Ms. Keeren Shah, Fin. Director (Age 44)
  • Dr. Thomas H. Adams, Head of Drug Devel. & Exec. Director (Age 78)
  • Dr. Neil Graham M.P.H., M.D., MPH, Chief Medical Officer
  • Dr. Napoleone Ferrara, Chairman of Scientific Advisory Board (Age 63)
  • Prof. Roberto Pellicciari, Consultant

Who are some of Tiziana Life Sciences' key competitors?

Some companies that are related to Tiziana Life Sciences include Dyne Therapeutics (DYN), VBI Vaccines (VBIV), Kadmon (KDMN), Provention Bio (PRVB), Collegium Pharmaceutical (COLL), Esperion Therapeutics (ESPR), AnaptysBio (ANAB), Merus (MRUS), Gossamer Bio (GOSS), OrganiGram (OGI), Calliditas Therapeutics AB (publ) (CALT), Odonate Therapeutics (ODT), Chinook Therapeutics (KDNY), Rigel Pharmaceuticals (RIGL) and Akouos (AKUS).
View all of TLSA's competitors.

What other stocks do shareholders of Tiziana Life Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tiziana Life Sciences investors own include Pfizer (PFE), Vaxart (VXRT), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Advanced Micro Devices (AMD), Moderna (MRNA), Enterprise Products Partners (EPD), Novavax (NVAX), Dynavax Technologies (DVAX) and Gilead Sciences (GILD).

When did Tiziana Life Sciences IPO?

(TLSA) raised $10 million in an initial public offering (IPO) on the week of November 19th 2018. The company issued 1,000,000 shares at a price of $9.90 per share. Laidlaw & Company (UK) Ltd. served as the underwriter for the IPO.

What is Tiziana Life Sciences' stock symbol?

Tiziana Life Sciences trades on the NASDAQ under the ticker symbol "TLSA."

Who are Tiziana Life Sciences' major shareholders?

Tiziana Life Sciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include HighTower Advisors LLC (6.31%), Renaissance Technologies LLC (0.56%), Orion Portfolio Solutions LLC (0.06%), Wells Fargo & Company MN (0.06%), Virtu Financial LLC (0.05%) and Ausdal Financial Partners Inc. (0.04%).

Which major investors are buying Tiziana Life Sciences stock?

TLSA stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, HighTower Advisors LLC, Virtu Financial LLC, Wells Fargo & Company MN, Orion Portfolio Solutions LLC, Golden Green Inc., Credit Suisse AG, and Ausdal Financial Partners Inc..

How do I buy shares of Tiziana Life Sciences?

Shares of TLSA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tiziana Life Sciences' stock price today?

One share of TLSA stock can currently be purchased for approximately $3.06.

How much money does Tiziana Life Sciences make?

Tiziana Life Sciences has a market capitalization of $196.51 million. The company earns $-9,320,000.00 in net income (profit) each year or ($0.03) on an earnings per share basis.

How many employees does Tiziana Life Sciences have?

Tiziana Life Sciences employs 8 workers across the globe.

What is Tiziana Life Sciences' official website?

The official website for Tiziana Life Sciences is www.tizianalifesciences.com.

Where are Tiziana Life Sciences' headquarters?

Tiziana Life Sciences is headquartered at 3RD FLOOR 11-12 ST. JAMES`S SQUARE, LONDON X0, SW1Y 4LB.

How can I contact Tiziana Life Sciences?

Tiziana Life Sciences' mailing address is 3RD FLOOR 11-12 ST. JAMES`S SQUARE, LONDON X0, SW1Y 4LB. The company can be reached via phone at 44-20-7495-2379 or via email at [email protected]


This page was last updated on 3/3/2021 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.